You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3
|
|---|---|
| Published in |
SpringerPlus, August 2016
|
| DOI | 10.1186/s40064-016-2920-z |
| Pubmed ID | |
| Authors |
Graham R. Foster, Kazuaki Chayama, Wan-Long Chuang, Hugo Fainboim, Martti Farkkila, Adrian Gadano, Giovanni B. Gaeta, Christophe Hézode, Yukiko Inada, Jeong Heo, Hiromitsu Kumada, Sheng-Nan Lu, Patrick Marcellin, Christophe Moreno, Stuart K. Roberts, Simone I. Strasser, Alexander J. Thompson, Joji Toyota, Seung Woon Paik, John M. Vierling, Anna L. Zignego, David Cohen, Fiona McPhee, Megan Wind-Rotolo, Subasree Srinivasan, Matthew Hruska, Heather Myler, Simon D. Portsmouth |
| Abstract |
Peginterferon Lambda was being developed as an alternative to alfa interferon for the treatment of chronic hepatitis C virus (HCV) infection. We compared peginterferon Lambda-1a plus ribavirin (Lambda/RBV) and Lambda/RBV plus daclatasvir (DCV; pangenotypic NS5A inhibitor) with peginterferon alfa-2a plus RBV (alfa/RBV) in treatment-naive patients with HCV genotype 2 or 3 infection. In this multicenter, double-blind, phase 3 randomized controlled trial, patients were assigned 2:2:1 to receive 24 weeks of Lambda/RBV, 12 weeks of Lambda/RBV + DCV, or 24 weeks of alfa/RBV. The primary outcome measure was sustained virologic response at post-treatment Week 12 (SVR12). Overall, 874 patients were treated: Lambda/RBV, n = 353; Lambda/RBV + DCV, n = 349; alfa/RBV, n = 172. Patients were 65 % white and 33 % Asian, 57 % male, with a mean age of 47 years; 52 % were infected with genotype 2 (6 % cirrhotic) and 48 % with genotype 3 (9 % cirrhotic). In the Lambda/RBV + DCV group, 83 % (95 % confidence interval [CI] 78.5, 86.5) achieved SVR12 (90 % genotype 2, 75 % genotype 3) whereas SVR12 was achieved by 68 % (95 % CI 63.1, 72.9) with Lambda/RBV (72 % genotype 2, 64 % genotype 3) and 73 % (95 % CI 66.6, 79.9) with peginterferon alfa/RBV (74 % genotype 2, 73 % genotype 3). Lambda/RBV + DCV was associated with lower incidences of flu-like symptoms, hematological abnormalities, and discontinuations due to adverse events compared with alfa/RBV. The 12-week regimen of Lambda/RBV + DCV was superior to peginterferon alfa/RBV in the combined population of treatment-naive patients with genotype 2 or 3 infection, with an improved tolerability and safety profile compared with alfa/RBV. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Philippines | 1 | 25% |
| Spain | 1 | 25% |
| United States | 1 | 25% |
| Unknown | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Finland | 1 | 4% |
| Unknown | 27 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 6 | 21% |
| Student > Doctoral Student | 3 | 11% |
| Student > Bachelor | 2 | 7% |
| Researcher | 2 | 7% |
| Professor | 2 | 7% |
| Other | 4 | 14% |
| Unknown | 9 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 36% |
| Biochemistry, Genetics and Molecular Biology | 3 | 11% |
| Economics, Econometrics and Finance | 2 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Mathematics | 1 | 4% |
| Other | 0 | 0% |
| Unknown | 11 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 May 2020.
All research outputs
#3,207,720
of 25,837,817 outputs
Outputs from SpringerPlus
#176
of 1,886 outputs
Outputs of similar age
#52,500
of 357,986 outputs
Outputs of similar age from SpringerPlus
#27
of 243 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,886 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 357,986 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 243 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.